NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis

Agios Pharmaceuticals, Inc. (AGIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AGIO

$37.18

+$0.54 (+1.47%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AGIO with… →

AGIO Key Statistics

As of Oct 21, 2026
Trading
Open
$36.62
Previous Close
$36.64
Day's Range
36.46–37.59
52-Week Range
22.24–46.00
Volume
849.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.63
Valuation
Market Cap
$2.22B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
22.57
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.01
Financials (FY)
Revenue (FY)
$54.03M+48.03%
Net Income (FY)
−$412.78M−161.27%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
59.70M
1-Year Return
−14.43%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.10M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AGIO closed at $37.18, −14.43% over 1 year.

Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $2.22B.

In fiscal 2025, AGIO reported revenue of $54.03M.

AGIO Stock Return by Calendar Year

Agios Pharmaceuticals, Inc. (AGIO) 10-year return: what $10,000 became

1 year
$10,000 $8,557
−14.43%
5 years
$10,000 $7,747
−22.53%
10 years
$10,000 $7,569
−24.31%

If you had invested $10,000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, at the close on October 21, 2016, it would have been worth $7,569 at the close on October 21, 2026: −24.31% in total, −2.75% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+36.59%
2025−17.16%
2024+47.55%
2023−20.69%
2022−14.57%
2021−24.14%
2020−9.26%
2019+3.56%
2018−19.35%
2017+37.00%
2016 (partial year)+2.71%

As of October 21, 2026.

AGIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$54.03M−$412.78M−764.0%
2024$36.50M$673.73M1,845.9%
2023$26.82M−$352.09M−1,312.6%
2022$14.24M−$231.80M−1,627.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$54.03M$47.68M−$472.13M−$412.78M−764.0%
2024$36.50M$32.33M−$425.74M$673.73M1,845.9%
2023$26.82M$23.94M−$391.49M−$352.09M−1,312.6%
2022$14.24M$12.54M−$389.05M−$231.80M−1,627.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AGIO Valuation vs Biotechnology Median

Median of 608 stocks
MetricAGIOBiotechnology medianvs median
P/S ratio22.5713.3070% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Agios Pharmaceuticals, Inc. (AGIO) carries a market capitalisation of $2.22B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 539 employees.

The 52-week range on file runs from $22.24 to $46.00. The most recent close on file for AGIO is $37.18, dated October 21, 2026. That is +$0.54 (+1.47%) against the previous close. The latest close sits 67.18% above that 52-week low.

Financial Health

In fiscal 2025, Agios Pharmaceuticals, Inc. reported revenue of $54.03M. That is +48.03% against the prior fiscal year, when revenue was $36.50M. The same year closed with a net loss of $412.78M. Trailing earnings per share are −7.01.

Across the 4 fiscal years on file, revenue moves from $14.24M in 2022 to $54.03M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 22.57 times revenue. On price-to-sales that is 69.74% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.63. Annualized volatility over the trailing 10 years is 56.32%. The trailing one-year total return is −14.43%. Measured over 10 years, that is −2.75% a year compounded.

Growth & Income

No dividend is on file for AGIO.

The strongest complete calendar year on file is 2024 at +47.55%; the weakest is 2021 at −24.14%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is +36.59% year to date.

Peer Comparison

Agios Pharmaceuticals, Inc. (AGIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Agios Pharmaceuticals, Inc. AGIO $2.22B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Agios Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Visit website →